| Pharmaceutical Information |
| Drug Name |
Methylnaltrexone |
| Drug ID |
BADD_D02462 |
| Description |
Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008. |
| Indications and Usage |
Treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy. |
| Marketing Status |
approved |
| ATC Code |
A06AH01 |
| DrugBank ID |
DB06800
|
| KEGG ID |
D06618
|
| MeSH ID |
C032257
|
| PubChem ID |
5361918
|
| TTD Drug ID |
D03YVO
|
| NDC Product Code |
Not Available |
| UNII |
0RK7M7IABE
|
| Synonyms |
methylnaltrexone | quaternary ammonium naltrexone | (5alpha)-17-(cyclopropylmethyl)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-17-ium-6-one | 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinanium-6-one | morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, (5alpha)- | morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)- | naltrexone methylbromide | N-methylnaltrexone bromide | morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, bromide, (5alpha,17R)- | naltrexone MB | naltrexone methobromide | methylnaltrexone bromide | methyl-naltrexone hydrobromide | MRZ 2663BR | Relistor | MRZ-2663 | naltrexonium methiodide |
|
| Chemical Information |
| Molecular Formula |
C21H26NO4+ |
| CAS Registry Number |
83387-25-1 |
| SMILES |
C[N+]1(CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
